Clinical trials: Esrd
End Stage Renal Disease
A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis
Malnutrition and altered protein catabolism are serious problems in renal failure and hemodialysis (HD) patients. The purpose of this study is to characterize the safety of GHRP-1/AG in subjects with ESRD on HD; to characterize…
- Trial name
- NCT00381602
- Testing
- GHRP-1/AG 70 mg depot in ESRD
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- QLT Inc.
Renal Impairment
A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function
The primary purpose of this study is to assess the effect of renal impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe renal…
- Trial name
- NCT05940402
- Testing
- Emraclidine
- Where
- 5 sites in United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- AbbVie
Chronic Kidney Diseases
A Mass Balance Study of [14C]HRS-1780 in Healthy Adult Male Subjects
The study aims to evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite identification of [14C]HRS-1780 following an oral single dose in healthy adult male participants.
- Trial name
- NCT07557407
- Testing
- [14C]HRS-1780
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Renal Failure
Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx
This study will evaluate the efficacy and safety of LCP-Tacro (tacrolimus) Tablets administered once-a-day compared to Prograf (tacrolimus) Capsules twice-a-day as immunosuppression for the prevention of organ rejection in newly…
- Trial name
- LCPTacro3002 (NCT01187953)
- Testing
- Prograf (tacrolimus), LCP-Tacro
- Where
- 86 sites in United States, Argentina and 13 more
- Volunteers
- 543 people
- Sponsor
- Veloxis Pharmaceuticals
Urinary Tract Infection, Kidney Failure
Healthy.io Method Comparison & User Performance Study
The objectives of the Healthy.io Method Comparison and User Performance Study are: 1. To evaluate the performance of Dip.io Device in comparison to the ACON U500 Mission® U500 Urine Analyzer. 2.
- Conditions
- Urinary Tract Infection, Kidney Failure, Diabetes
- Trial name
- NCT02785445
- Testing
- Dip.io Home Based Dipstick Analyzer, ACON U500 Mission® U500 Urine Analyzer
- Where
- 2 sites in United States
- Volunteers
- 425 people, healthy volunteers welcome
- Sponsor
- Healthy.io Ltd.
Chronic Kidney Disease
A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease
This study is open to adults who have kidney disease that is not caused by diabetes. The purpose of the study is to find out whether a medicine called avenciguat (BI 685509) improves kidney function.
- Trial name
- NCT04736628
- Testing
- Avenciguat
- Where
- 110 sites in United States, Argentina and 16 more
- Volunteers
- 261 people
- Sponsor
- Boehringer Ingelheim
Alzheimer's Disease
A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])
This study will assess the pharmacokinetics of MK-8931, a ß-secretase inhibitor, in participants with renal insufficiency. In Part 1 of the study, pharmacokinetics of MK-8931 in participants with severe renal disease and in…
- Trial name
- NCT01537757
- Testing
- MK-8931
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Renal Failure
A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
To investigate the safety, pharmacokinetics, pharmacodynamics, and efficacy of OPC-41061 in patients with chronic renal failure undergoing hemodialysis or hemodiafiltration using variables, such as daily urine volume and increase…
- Trial name
- NCT01876381
- Testing
- OPC-41061
- Where
- 5 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Chronic Kidney Disease, Type 2 Diabetes Mellitus
A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.
- Trial name
- NCT01847092
- Testing
- AZD1722
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Ardelyx
Renal Impairment
A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment
The primary objectives of this study are to evaluate the pharmacokinetics (PK) following administration of gabapentin in Japanese epileptic patients with renal impairment to confirm if there are any clinically relevant…
- Trial name
- NCT00785772
- Testing
- Gabapentin
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Renal Failure Chronic Requiring Hemodialysis
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
The purpose of this study is to confirm the safety and efficacy of Soluble Ferric Pyrophosphate (SFP) dialysate solution in maintaining iron delivery for erythropoiesis in anemic adult patients with chronic kidney disease (CKD)…
- Trial name
- CRUISE 1 (NCT01320202)
- Testing
- Soluble Ferric Pyrophosphate (SFP), Standard dialysate
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 305 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Chronic Renal Failure Requiring Hemodialysis
A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
The purpose of the study is to determine the long-term safety in treatment-emergent adverse events (TEAEs) of intravenous (IV) administration of Epoetin Hospira for maintenance of target hemoglobin (Hgb) levels in patients…
- Trial name
- AiME - 03 (NCT01628107)
- Testing
- Epoetin Hospira
- Where
- 110 sites in United States, Puerto Rico
- Volunteers
- 406 people
- Sponsor
- Pfizer
End Stage Renal Disease
Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects
This study will assess the pharmacokinetics, safety and tolerability of aliskiren in healthy subjects and patients with End Stage Renal Disease on hemodialysis.
- Trial name
- NCT01568775
- Testing
- Aliskiren
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Novartis
HCV Infection
Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency
The primary objectives of this study are to evaluate the safety and efficacy of sofosbuvir (SOF) plus ribavirin (RBV) for 24 weeks and ledipasvir/sofosbuvir (LDV/SOF) for 12 weeks, and to evaluate the steady state…
- Trial name
- NCT01958281
- Testing
- SOF, RBV, LDV/SOF
- Where
- 10 sites in United States, New Zealand and 1 more
- Volunteers
- 38 people
- Sponsor
- Gilead Sciences
Coronary Artery Disease, Renal Impairment
Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography
The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the…
- Trial name
- NCT00209430
- Testing
- Iodixanol 320 mgI/mL
- Where
- Sweden
- Volunteers
- 408 people
- Sponsor
- GE Healthcare
Anemia in Chronic Kidney Disease in Non-dialysis Patients
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
This study was conducted to treat anemia in patients with chronic kidney disease. Anemia is a reduced number of red blood cells or hemoglobin. Hemoglobin is important for the transport of oxygen in your blood.
- Trial name
- ALPS (NCT01887600)
- Testing
- Roxadustat
- Where
- 138 sites in Belarus, Belgium and 20 more
- Volunteers
- 594 people
- Sponsor
- Astellas Pharma Europe B.V.
Chronic Kidney Disease
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.
- Trial name
- NCT04492722
- Testing
- AZD5718, Dapagliflozin 10 mg
- Where
- 111 sites in United States, Argentina and 9 more
- Volunteers
- 613 people
- Sponsor
- AstraZeneca
Red-Cell Aplasia, Pure
A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins
The purpose of this study is to record the number of participants with chronic renal disease who are receiving treatment with epoetin alfa or other recombinant erythropoietins who develop pure red cell aplasia (PRCA, a rare form…
- Trial name
- NCT00211029
- Volunteers
- 4,670 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Kidney Diseases, Kidney Injury, Acute
Clinical Performance of a Point-of-Care Creatinine Testing System in Individuals With Kidney Disease
The goal of this clinical performance study is to evaluate the accuracy and usability of the Eaglenos Creatinine Test System（referred to as EG）, a point-of-care testing (POCT) system that consists of a handheld device and its…
- Trial name
- NCT07251075
- Testing
- Reference Creatinine Test System（Cobas c 111）, Investigational Creatinine Test System （EG）
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tingting Xu
Secondary Hyperparathyroidism, Chronic Kidney Disease
Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
MT1013 is a first-in-class dual-target agonist. This study is a multicenter, randomized, double-blind, double-dummy phase III clinical study being conducetd to evaluate the efficacy and safety of MT1013 compared with active…
- Trial name
- NCT07122401
- Testing
- MT1013, Cinacalcet
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.